High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy have?
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy has 136 citations in the OpenAlex counts ScholarIQ stores.
When was High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy published?
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy has 2019 year in the ScholarIQ index.
What is the open-access status of High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy?
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy has green oa status in the ScholarIQ index.
What is the DOI of High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy?
The DOI for High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy is on the source record.
What is the PMID of High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy?
The PMID for High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy is on the source record.
What is the OpenAlex record for High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy?
The OpenAlex for High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy is on the source record.